FDA Brief

Warning letters Food

FDA warning letter to

Nutritional Laboratories International, Inc. DBA Elite One Source Nutritional Services, Inc.

MediumIssued Aug 5, 2022Posted Aug 30, 2022Office of Human and Animal Food Operations – West Division 6

FDA warns Nutritional Laboratories International over CGMP violations and misbranded dietary supplement labels found after 2021 inspection.

What happened

FDA inspected the Missoula, Montana facility on September 14-17 and 28, 2021, and collected product labels. FDA found serious CGMP violations for dietary supplements, including failure to verify finished batches met specifications, failure to follow quality control procedures for complaints, and inadequate laboratory methods and reference standards. FDA also found several products misbranded because serving sizes and Supplement Facts information did not meet labeling rules.

What FDA found

  1. The firm did not adequately verify that finished dietary supplement batches met specifications for identity, purity, strength, composition, and contamination limits.

    21 CFR 111.75(c)
  2. Quality control did not follow its written procedure to review and approve complaint investigation decisions.

    21 CFR 111.103
  3. The firm used FTIR identity testing for blends even though it could not identify individual ingredients in those blends.

    21 CFR 111.320(a)
  4. The firm used previously released lots as reference standards without established criteria or full characterization and quality control approval.

    21 CFR 111.315(d); 21 CFR 111.110(a)
  5. Some products listed an incorrect serving size compared with the label directions.

    section 403(q)(1)(A) of the Act; 21 CFR 101.9(b); 21 CFR 101.12(b) Table 2
  6. Some labels were misbranded because Supplement Facts formatting and ingredient common names did not meet requirements.

    section 403(q)(5)(F) and 403(i)(2) of the Act; 21 CFR 101.36; 21 CFR 101.4

What FDA wants

Within 15 working days, notify FDA in writing of steps taken to correct violations, prevent recurrence, and provide documentation; if corrective actions cannot be completed, explain the delay and when they will be done.

Who should pay attention

  • brands that use this contract manufacturer for dietary supplements
  • dietary supplement companies relying on FTIR identity testing
  • labeling and quality teams for supplement brands

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk